Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726860 | 1.00 | PDE10A (0.71) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL14726852 | 0.88 | PDE10A (0.77) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL14722614 | 0.88 | PDE10A (0.77) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL15940262 | 0.86 | PDE10A (0.74) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL14721169 | 0.86 | PDE10A (0.74) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL15940179 | 0.86 | PDE10A (0.54) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL14723007 | 0.86 | PDE10A (0.54) | PDE10AKCNH2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL14722850 | 0.85 | PDE10A (0.85) | PDE10AKCNH2SSTR2 | |
| SCHEMBL14723267 | 0.85 | PDE10A (0.85) | PDE10AKCNH2SSTR2 | |
| SCHEMBL14721039 | 0.85 | PDE10A (0.85) | PDE10AKCNH2SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748151-B1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-16 | — | — | EP | claimed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| EP-2748151-A1 | PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-02 | — | — | EP | claimed |
| WO-2013028590-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | PDE12, PDE10A, PDE11A | PDE10A 2/4885KCNH2 2618/4885NR1I2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.